References
- Watkins PB, Seligman PJ, Pears JS, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology. 2008;48:1680–1689.
- Chen M, Suzuki A, Borlak J, et al. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol. 2015;63:503–514.
- De Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004;58:71–80.
- http://livertox.nih.gov/. Accessed 19 November 2015.
- Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451–455.
- Bjornsson ES, Bergmann OM, Bjornsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419–1425.
- Goldberg DS, Forde KA, Carbonari DM, et al. Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated healthcare system. Gastroenterology. 2015;148:1353–1361.
- Dara L, Liu Z, Kaplowitz N, Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. 2015; [Oct 20]. doi:10.1111/liv.12988.
- Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–521.
- Bessone F, Hernández N, Sánchez A, et al. A comparative analysis of the Spanish and Latin-American prospective drug-induced liver injury (DILI) networks. Hepatology. 2015;62:504A.
- Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148:1340–1352.
- Spanish DILI Registry. Málaga (Spain). [cited 2015 Nov 21]. Available from: www.spanishdili.uma.es
- Spanish Latin American DILI Network. [cited 2015 Nov 21]. Available from: www.slatindili.uma.es
- Drug-Induced Liver Injury Network. Bethesda (MD): The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). [cited 2015 Nov 21]. Available from: http://www.dilin.org/
- Robles-Diaz M, Lucena MI, Kaplowitz N, et al. Use of Hy’s Law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014;147:109–118.
- Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009;49:2001–2009.
- Stephens C, Andrade RJ, Lucena MI. Mechanisms of drug-induced liver injury. Curr Opin Allergy Clin Immunol. 2014;14:286–292.
- Aithal GP. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Intern. 2015;35:1801–1808.
- Teschke R, Andrade RJ. Drug-induced liver injury: expanding our knowledge by enlarging population analysis with prospective and scoring causality assessment. Gastroenterology. 2015;148:1271–1273.